SuperworthProkidney market cap PROK
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $426.3M
- Highest close in our data
- $3B
- Aug 2023
Prokidney is worth $426.3M at the close on Oct 23, 2026, at $1.41 a share.
That is down 55% over the last year and up 34% over five years.
Its highest close in our data was $3B in Aug 2023.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $426.3M | $402.1M | $704M | −44% |
| 2025 | $761.1M | $175.4M | $1.3B | +54% |
| 2024 | $495.8M | $287.2M | $940.7M | +18% |
| 2023 | $419.1M | $284.9M | $3B | −74% |
| 2022 | $1.6B | $223.9M | $2.6B | +406% |
| 2021 | $315.7M | $310.7M | $318.1M | n/a |
Against its peers
Companies in Biotechnology nearest Prokidney's size, closest first, today.
| Company | Market cap |
|---|---|
| PROKProkidney | $426.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| MGTXMeiraGTx | $884.6M |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Prokidney
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.